Skip to main content
. 2024 Aug 29;10(17):e36885. doi: 10.1016/j.heliyon.2024.e36885

Table 6.

Relative treatment effects (RTE) table for PSS from the non-parametric longitudinal factorial analysis.

Group Time Count RankMeans RTE Bias Variance Lower Upper
Placebo BLa 20 131.95 0.7303 5.00E-04 0.0317 0.6821 0.7721
Placebo D30 20 113.075 0.6254 −6.00E-04 0.0546 0.5642 0.6818
Placebo D60 20 117.9 0.6522 1.00E-04 0.0457 0.5958 0.7036
AE120 BL 20 136 0.7528 0.00E+00 0.0697 0.6777 0.8112
AE120 D30 20 54.25 0.2986 4.00E-04 0.0114 0.2725 0.3266
AE120 D60 20 17.925 0.0968 −4.00E-04 0.0113 0.0768 0.1338
AE60 BL 20 147.925 0.819 0.00E+00 0.0523 0.7494 0.8666
AE60 D30 20 67.575 0.3726 1.00E-04 0.0167 0.3407 0.4061
AE60 D60 20 27.9 0.1522 −1.00E-04 0.0138 0.1263 0.1862
a

BL: Baseline; RTE tending below 0.5 means that AE60 and AE120 were able to considerably reduce the PSS scores whereas placebo can be seen with minimal change to the RTE. The systematic deviation of the estimated treatment effect from the true treatment effect is given as the bias. How much the estimated treatment effects vary across different samples or iterations of the analysis is given by the variance.